Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Case report of the use of teclistamab for treatment of relapsed/refractory POEMS syndrome producing a durable biochemical and radiographic remission lasting past drug discontinuation and without any unanticipated toxicities.”
Title: Teclistamab for heavily pretreated relapsed/refractory POEMS syndrome
Authors: Alexis Talbot, Nathalie Forgeard, Tristan Vaugeois, Floriane Theves, Sabrine Dimassi, Bruno Royer, Pierre-Edouard Debureaux, Véronique Meignin, Laetitia Vercellino, David Boutboul, Bertrand Arnulf, Stéphanie Harel
You can read the Full Article in Haematologica.
You can find more posts featuring Robert Orlowski in OncoDaily.
